An analysis of the NRG Oncology clinical trial NRG-RTOG 9202 showed that the interval of time to biochemical failure (IBF), or the time it takes for previously treated cancer to return as indicated by ...
Validated Measurable Residual Disease Assays are Critical for the Rapid Development of Future Novel Therapeutics for Patients with Acute Myeloid Leukemia SPRING HOUSE, Pa., May 5, 2022 /PRNewswire/ -- ...
This milestone opens a path for FibroScan ® to ultimately replace liver biopsy for patient enrollment and treatment response assessment in MASH drug development WESTBOROUGH, Mass., Sept. 8, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback